Enovis Co. (NYSE:ENOV) Receives $67.00 Average Target Price from Analysts

Shares of Enovis Co. (NYSE:ENOV) have earned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $67.00.

Several research analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Evercore ISI reduced their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. Finally, JMP Securities initiated coverage on shares of Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target on the stock.

Hedge Funds Weigh In On Enovis

Large investors have recently bought and sold shares of the business. Ridgewood Investments LLC acquired a new position in Enovis during the second quarter worth $44,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Enovis during the 3rd quarter worth about $55,000. Innealta Capital LLC purchased a new position in Enovis in the 2nd quarter valued at about $65,000. Benjamin F. Edwards & Company Inc. boosted its holdings in Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares during the last quarter. Finally, FMR LLC increased its stake in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of Enovis stock opened at $45.65 on Friday. The company has a 50 day moving average price of $44.38 and a 200 day moving average price of $44.56. The firm has a market capitalization of $2.55 billion, a P/E ratio of -20.84 and a beta of 1.94. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis has a 52 week low of $38.27 and a 52 week high of $65.03.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter last year, the company posted $0.56 earnings per share. The business’s quarterly revenue was up 21.0% on a year-over-year basis. Sell-side analysts expect that Enovis will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.